title: [Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
authors.affiliation: Dept. of Infections Diseases, Hamamatsu Medical Center.
authors.forename: K
authors.initials: K
authors.lastname: Yano
authors.forename: H
authors.initials: H
authors.lastname: Matsui
authors.forename: S
authors.initials: S
authors.lastname: Fujisawa
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001088:Arabinonucleotides / Q000008:administration & dosage*; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage*; D011788:Quality of Life
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D001088:Arabinonucleotides; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D017294:Ondansetron; D003568:Cytidine Monophosphate